Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Stock Is Nosediving Today

By Keith Speights - May 10, 2021 at 12:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced a senior convertible notes offering.

What happened

Shares of Dynavax Technologies (DVAX -2.41%) were nosediving 18.1% lower as of 11:42 a.m. EDT on Monday. The decline came after the company announced plans to offer $200 million in convertible senior notes due in 2026.

So what

The key word to note in Dynavax's announcement is "convertible." The notes that the company plans to issue will be able to be converted into shares. That means the value of Dynavax's existing shares could be diluted. When investors hear about potential dilution, they often head for the hills and create downward pressure on share prices. That's almost certainly why the biotech stock fell today.

$1 bill folded into an arrow pointing down

Image source: Getty Images.

Issuing convertible notes is a common practice for companies, though. Dynavax plans to use the proceeds raised to pay off debt and other obligations under its term loan agreement.

However, the company also intends to use some of the money to pay for capped call transactions. These are call options that will give Dynavax the right to purchase its own shares at a specified price. The company said that it expects these capped call transactions will offset the potential dilution to its stock.

Now what

There are several more important things for investors to watch with Dynavax than its convertible notes offering. Several of the company's partners will report results from clinical studies of COVID-19 vaccines that use Dynavax's CpG 1018 adjuvant this year. Dynavax also plans to launch hepatitis B vaccine Heplisav-B in Europe in the fourth quarter.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$12.17 (-2.41%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.